Contineum Therapeutics Class A Common Stock Statistics
Share Statistics
Contineum Therapeutics Class A Common Stock has 25.87M
shares outstanding. The number of shares has increased by 0.58%
in one year.
| Shares Outstanding | 25.87M |
| Shares Change (YoY) | 0.58% |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | 80.91% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 65 |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 577.64K, so 2.23% of the outstanding
shares have been sold short.
| Short Interest | 577.64K |
| Short % of Shares Out | 2.23% |
| Short % of Float | 3.41% |
| Short Ratio (days to cover) | 7 |
Valuation Ratios
The PE ratio is -6.71 and the forward
PE ratio is -1.33.
Contineum Therapeutics Class A Common Stock's PEG ratio is
0.03.
| PE Ratio | -6.71 |
| Forward PE | -1.33 |
| PS Ratio | 0 |
| Forward PS | 4 |
| PB Ratio | 1.43 |
| P/FCF Ratio | -8.5 |
| PEG Ratio | 0.03 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Contineum Therapeutics Class A Common Stock.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.69,
with a Debt / Equity ratio of 0.03.
| Current Ratio | 20.69 |
| Quick Ratio | 20.69 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.19 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,030,682.93 |
| Employee Count | 41 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -75.52% in the
last 52 weeks. The beta is 0.7, so Contineum Therapeutics Class A Common Stock's
price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -75.52% |
| 50-Day Moving Average | 5.71 |
| 200-Day Moving Average | 12.91 |
| Relative Strength Index (RSI) | 32.42 |
| Average Volume (20 Days) | 66,222 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -50.89M |
| Net Income | -42.26M |
| EBITDA | -42M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.18 |
Full Income StatementBalance Sheet
The company has 21.94M in cash and 6.26M in
debt, giving a net cash position of 15.68M.
| Cash & Cash Equivalents | 21.94M |
| Total Debt | 6.26M |
| Net Cash | 15.68M |
| Retained Earnings | -117.4M |
| Total Assets | 212.85M |
| Working Capital | 196.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -32.84M
and capital expenditures -514K, giving a free cash flow of -33.36M.
| Operating Cash Flow | -32.84M |
| Capital Expenditures | -514K |
| Free Cash Flow | -33.36M |
| FCF Per Share | -1.72 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
